Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gautschi, O.
Right arrow Articles by Stahel, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gautschi, O.
Right arrow Articles by Stahel, R. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:170, 2003
© 2003 European Society for Medical Oncology

Letters to the Editor

Comment on "A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer", by C. M. Rudin et al. (Ann Oncol 2002; 13: 539–545)

O. Gautschi*,1, U. Zangemeister-Wittke2 and R. A. Stahel2

1 Division of Medical Oncology, University Hospital, Bern; 2 Division of Medical Oncology, University Hospital, Zürich, Switzerland

*E-mail: oliver_gautschi@hotmail.com

The first 10% of the full text of this article appears below.

In their pilot study, Rudin et al. describe the safety, feasibility and toxicity profile of the combination of paclitaxel and G3139 (GenasenseTM), a bcl-2 antisense oligonucleotide, in patients with chemoresistant small-cell lung cancer (SCLC). Tolerance . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?